Ameling et al. (2016) demonstrated that immunoadsorption with subsequent immunoglobulin substitution (IA/IgG) improved LVEF, LVIDD, and NYHA classes and inflammation status in DCM patients, accompanied by lower expression of connective tissue growth factor, fibronectin, and collagen type I. However, the response rates to this therapeutic intervention are characterized by considerable interindividual variability (Ameling et al., 2013). This evidence concerns the gene FN1 and familial dilated cardiomyopathy.